Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Fagron: Turnover growth supported by key regions Europe, South America and North America

Fagron NV
Posted on: 12 Oct 17

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands) 1 , 12 October 2017

Key points

  • Turnover increases to € 103.6 million
  • Organic turnover growth at constant exchange rates of 2.4%
  • Active buy-and-build strategy:
    • Acquisition of Croatian Kemig in August
    • Acquisition of Brazilian All Chemistry in October

Hans Stols, CEO of Fagron : "Fagron reported solid results in the third quarter of 2017. The comparable turnover at constant exchange rates from our activities increased by 2.4%. Our activities in Europe showed good results in the third quarter. This growth was reduced, however, by the backlog at external laboratories that analyse the raw materials Fagron purchases. Limited product availability resulting from this delay in the analysis process caused delays in the supply of raw materials to our customers. Those involved are working hard on a solution and we expect the backlog in delivery to be largely cleared in the first quarter of 2018. Our activities in South America realised turnover growth at constant exchange rates of 3.4%, while our activities in North America achieved turnover growth of 4.1%. The sterile activities in the United States grew by 17.6%.

As part of its active buy-and-build strategy, Fagron is constantly in talks with various parties to consolidate our leading positions in our keys regions, Europe and North and South America. Over the past several months, we expanded our activities with two acquisitions. We finalised the acquisition of Kemig at the beginning of August, further consolidating our leading position in Europe. Kemig is a leading supplier of pharmaceutical raw materials and packaging materials to pharmacies and wholesalers in Croatia and Bosnia and Herzegovina. At the beginning of October we announced the acquisition of Brazil-based All Chemistry, a renowned supplier of pharmaceutical raw materials for compounding pharmacies.

We remain positive about the growth opportunities we see in the various markets in which we are active."

Turnover (x € 1,000)Q3 2017Q3 2016Total growthTotal growth CEROrg. growthOrg. growth CER
HL Technology1,8021,538+17.2%+21.5%+17.2%+21.5%
Fagron Group 103,585 103,401 +0.2% +1.2% +1.3% +2.4%
Turnover (x € 1,000)9M 20179M 2016Total growthTotal growth CEROrg. growthOrg. growth CER
HL Technology5,2636,097-13.7%-13.6%-13.7%-13.6%
Fagron Group 325,311 313,637 +3.7% +0.9% +4.4% +1.6%
CER = constant exchange rates
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

1 This press release was sent out by Fagron NV and Fagron BV.

Please open the link below for the press release:
Turnover growth supported by key regions Europe, South America and North America

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Fagron NV via GlobeNewswire

Last updated on: 13/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.